{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinson’s disease (PD). The I2020T and G2019S mutations are located in the activation loop of the kinase domain and alter kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links LRRK2 mutations to PD and identifies the variants as altering kinase activity, which is central to the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Binding and enzymatic assays were used to assess ATP affinity and kinase inhibitor sensitivity, which are standard methods for evaluating kinase activity and inhibitor interactions.",
          "judgment": "Yes",
          "reasoning": "The assays align with established practices in kinase research and directly relate to the molecular mechanism of the disease."
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "Experiments were performed with wild-type and mutant proteins, and results were reported as 'performed in triplicate.'",
          "judgment": "Yes",
          "reasoning": "The paper describes use of wild-type controls and triplicate experiments, meeting criteria for basic controls and replicates."
        },
        {
          "step_name": "Step 3c: Variant controls",
          "extracted_paper_info": "The study does not explicitly mention using known pathogenic or benign variants as controls for these specific mutations.",
          "judgment": "No",
          "reasoning": "While controls are present, the paper does not state that known pathogenic/benign variants were used as controls for these specific mutations."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper reports fold differences in ATP affinity (e.g., G2019S: 1.6-fold more sensitive; I2020T: 10-fold more resistant) but does not provide OddsPath values or explicit statistical tests.",
          "judgment": "No",
          "reasoning": "The study reports effect sizes but lacks OddsPath calculations or detailed statistical analysis."
        }
      ],
      "final_evidence_strength": "PS3_moderate",
      "reasoning": "The assays are valid and controls are present, but the absence of OddsPath and limited control variants (not explicitly stated) leads to a moderate PS3 classification based on the observed effect sizes."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "A",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinson’s disease (PD). The I2020T and G2019S mutations are located in the activation loop of the kinase domain and alter kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links LRRK2 mutations to PD and identifies the variants as altering kinase activity, which is central to the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Binding and enzymatic assays were used to assess ATP affinity and kinase inhibitor sensitivity, which are standard methods for evaluating kinase activity and inhibitor interactions.",
          "judgment": "Yes",
          "reasoning": "The assays align with established practices in kinase research and directly relate to the molecular mechanism of the disease."
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "Experiments were performed with wild-type and mutant proteins, and results were reported as 'performed in triplicate.'",
          "judgment": "Yes",
          "reasoning": "The paper describes use of wild-type controls and triplicate experiments, meeting criteria for basic controls and replicates."
        },
        {
          "step_name": "Step 3c: Variant controls",
          "extracted_paper_info": "The study does not explicitly mention using known pathogenic or benign variants as controls for these specific mutations.",
          "judgment": "No",
          "reasoning": "While controls are present, the paper does not state that known pathogenic/benign variants were used as controls for these specific mutations."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper reports fold differences in ATP affinity (e.g., G2019S: 1.6-fold more sensitive; I2020T: 10-fold more resistant) but does not provide OddsPath values or explicit statistical tests.",
          "judgment": "No",
          "reasoning": "The study reports effect sizes but lacks OddsPath calculations or detailed statistical analysis."
        }
      ],
      "final_evidence_strength": "PS3_moderate",
      "reasoning": "The assays are valid and controls are present, but the absence of OddsPath and limited control variants (not explicitly stated) leads to a moderate PS3 classification based on the observed effect sizes."
    }
  ]
}